104 related articles for article (PubMed ID: 9305673)
1. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.
Teuber G; Berg T; Naumann U; Raedle J; Brinkmann S; Hopf U; Zeuzem S
J Viral Hepat; 2001 Jul; 8(4):276-83. PubMed ID: 11454179
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for beneficial response to interferon-alfa therapy in chronic hepatitis C.
Yoon SK; Kim SS; Park YM; Shim KS; Lee CD; Sun HS; Park DH; Kim BS; Ryu WS; Cho JM
Korean J Intern Med; 1995 Jul; 10(2):94-102. PubMed ID: 7495780
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.
Wilder J; Saraswathula A; Hasselblad V; Muir A
J Natl Med Assoc; 2016 Feb; 108(1):24-9. PubMed ID: 26928485
[TBL] [Abstract][Full Text] [Related]
4. Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
Suo SS; Fu RF; Qin A; Shao ZH; Bai J; Chen SN; Duan MH; Zhou H; Xu N; Zhang SJ; Zuo XL; Du X; Wang L; Li P; Zhang XH; Wu DX; Li YN; Zhang JJ; Wang W; Shen WH; Zagrijtschuk O; Sato T; Xiao ZJ; Jin J
J Hematol; 2024 Apr; 13(1-2):12-22. PubMed ID: 38644985
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.
Liu WD; Feng PH; Cheng CY; Chou CL; Lee CH; Lu MC; Liu PY; Lee MH; Liao CH; Chen MC; Chen CP; Hsu SF; Tzeng YT; Lin YC; Ou TY; Qin A; Tsai CY; Shih WJ; Lee KY; Sheng WH
Infect Dis Ther; 2024 May; ():. PubMed ID: 38771550
[TBL] [Abstract][Full Text] [Related]
6. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
Ann Hematol; 2024 Mar; ():. PubMed ID: 38438627
[TBL] [Abstract][Full Text] [Related]
7. Psychiatric care of the patient with hepatitis C: a review of the literature.
Rifai MA; Gleason OC; Sabouni D
Prim Care Companion J Clin Psychiatry; 2010; 12(6):. PubMed ID: 21494349
[TBL] [Abstract][Full Text] [Related]
8. Interferon alpha-induced lupus: proof of principle.
Niewold TB
J Clin Rheumatol; 2008 Jun; 14(3):131-2. PubMed ID: 18525429
[No Abstract] [Full Text] [Related]
9. Clinical Observation of Reduning Combined with Recombinant Human Interferon
Li Z; Xie L; Wang H; Wang S; Wu J
Evid Based Complement Alternat Med; 2022; 2022():1739561. PubMed ID: 35747380
[TBL] [Abstract][Full Text] [Related]
10. Retracted: Clinical Observation of Reduning Combined with Recombinant Human Interferon
And Alternative Medicine EC
Evid Based Complement Alternat Med; 2023; 2023():9831716. PubMed ID: 38125189
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.
Artico S; Amaral KM; Gonçalves CB; Picon PD
BMC Infect Dis; 2012 Dec; 12():377. PubMed ID: 23270376
[TBL] [Abstract][Full Text] [Related]
12. Review of consensus interferon in the treatment of chronic hepatitis C.
Witthöft T
Biologics; 2008 Dec; 2(4):635-43. PubMed ID: 19707444
[TBL] [Abstract][Full Text] [Related]
13. Interferons and their use in persistent viral infections.
Chevaliez S; Pawlotsky JM
Handb Exp Pharmacol; 2009; 189(189):203-41. PubMed ID: 19048202
[TBL] [Abstract][Full Text] [Related]
14. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.
Mathew A; Peiffer LP; Rhoades K; McGarrity T
Dig Dis Sci; 2006 Nov; 51(11):1956-61. PubMed ID: 17004124
[TBL] [Abstract][Full Text] [Related]
15. Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism.
Nguyen VA; Chen J; Hong F; Ishac EJ; Gao B
Biochem J; 2000 Jul; 349(Pt 2):427-34. PubMed ID: 10880341
[TBL] [Abstract][Full Text] [Related]
16. Chronic viral hepatitis C: management update.
Gutfreund KS; Bain VG
CMAJ; 2000 Mar; 162(6):827-33. PubMed ID: 10750473
[TBL] [Abstract][Full Text] [Related]
17. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
